ATTAIN-1: orforglipron, a once-daily oral small-molecule GLP-1, for obesity

Orforglipron is not a peptide. It is a small molecule taken as a daily tablet without the fasting rules that oral semaglutide needs. ATTAIN-1 is its pivotal obesity trial.

What the trial asked

Whether once-daily oral orforglipron at 6, 12 or 36 mg reduces body weight compared with placebo in adults with obesity and no diabetes, as an adjunct to diet and physical activity.

Design

Phase 3, multinational, randomised 3:3:3:4, double-blind, placebo-controlled, 72 weeks. Primary endpoint: percent change in body weight from baseline to week 72, treatment-regimen estimand, intention-to-treat population.

Who was enrolled

3127 adults with obesity without diabetes mellitus. The abstract gives no further baseline detail.

Primary endpoint and result

P less than 0.001 for every comparison with placebo.

Key secondary results

In the 36 mg group, 54.6 percent lost 10 percent or more, 36.0 percent lost 15 percent or more, and 18.4 percent lost 20 percent or more, against 12.9, 5.9 and 2.8 percent on placebo. Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol improved significantly versus placebo; the abstract does not give the values.

Adverse events and discontinuation

The most common adverse events were gastrointestinal, mostly mild to moderate. Adverse events led to treatment discontinuation in 5.3 to 10.3 percent of the orforglipron groups and 2.7 percent of the placebo group. The abstract describes the profile as consistent with other GLP-1 receptor agonists.

Funding and registration

Eli Lilly. ClinicalTrials.gov NCT05869903.

What this trial does not show

• The top-dose result (-11.2 percent) is smaller than injectable semaglutide 2.4 mg in STEP 1 (-14.9 percent) or tirzepatide in SURMOUNT-1. Those are different trials with different populations; the gap is indicative, not a head-to-head finding.
• The abstract does not report baseline weight, so the percent figures cannot be turned into kilograms from this page.
• No comparison with oral semaglutide.
• A follow-on trial, ATTAIN-MAINTAIN (PubMed 42120723), tested orforglipron as maintenance after injectable therapy in participants from SURMOUNT-5. Its abstract reports that participants who had plateaued on tirzepatide kept a model-based 74.7 percent of their weight reduction on orforglipron versus 49.2 percent on placebo at week 52, and those from semaglutide kept 79.3 versus 37.6 percent. The paper itself notes the absence of a continued-injectable comparator arm as a limitation. It is cited here, not digested in full.

Where the numbers come from

PubMed abstracts of ATTAIN-1 (PubMed 40960239) and ATTAIN-MAINTAIN (PubMed 42120723), fetched 4 September 2026. The diabetes counterpart is ATTAIN-2.